SPAGO — Spago Nanomedical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK88.14m
- SEK62.21m
- SEK0.44m
Brief: Spago Nanomedical Reports Favorable Data In Breast Cancer Model With Tumorad
Brief: Spago Nanomedical Q4 Sales SEK 731 Thousand
Brief: Spago Nanomedical To Report Data From Phase I Part Of Tumorad-01 Study Later In H1
Advisory: Alerts on positive data in Spago's phase IIa endometriosis trial repeat earlier story
Brief: Spago Nanomedical Carries Out Directed Issue Of Shares
Brief: Spago Nanomedical Q3 Sales at SEK 271 Thousand
Brief: Spago Nanomedical Applies For Extended Patent Protection For Tumorad®
Brief: Spago Nanomedical Receives Approval To Start Clinical Phase I/Iia
Brief: Spago Nanomedical Proposes Rights Issue Of Units Of About SEK 30.6 Mln
Brief: Spago Nanomedical Q2 Sales at SEK 114 Thousand
Brief: Spago Nanomedical Updates On Clinical Phase IIa Study Spagopix-02
Brief: Spago Nanomedical Submits Application To Start Tumorad Phase I/IIa Study
Brief: Spago Q1 Loss SEK 14.4 Million
Brief: Spago Nanomedical Q1 Adj. EPS at SEK -0.16
Brief: Spago Nanomedical Proposes Hans Arwidsson As New Chairman
Brief: Spago Nanomedical Q4 Net Sales Rises To SEK 142,000
Brief: Spago Nanomedical Terminates Liquidity Guarantee
Brief: Spago Q3 Loss Narrows To SEK 8.6 Mln
Brief: Spago Q2 Loss Narrows To SEK 9.6 Mln